Individual analysis shows that Cx46 also negatively correlated with patient survival, whereas Cx43 did not show any significant correlation (C). Statistical assessments were performed using log-rank survival analysis, and p-values are indicated directly on survival plots.
Supplemental Experimental Procedures
GBM cell collection, culture, and usage GBM cells were dissociated from primary patient-derived tumors using a papain dissociation system (Worthington). GBM cells were maintained by successive subcutaneous xenografting into immunocompromised nude mice (nu/nu, Jackson Laboratory) in accordance with IACUCapproved protocols. The cells used for in vitro analysis were dissociated from xenograft tumors using the papain dissociation system. The molecular subtype of each xenograft was generated by comparison with gene array data in The Cancer Genome Atlas dataset; T4121 represents the classical subtype, and T387 represents the mesenchymal subtype (Cancer Genome Atlas Research, 2008) . Detailed pathological information is provided in previous publications (Bao et al., 2006; Eyler et al., 2011) . The cells with CSC properties were enriched by their high expression levels of CD133 using a MACS manual cell separation kit (Miltenyi). The cells that did not bind to CD133 antibody-coated beads in this process (CD133-cells) were collected and used as non-CSCs. This approach has previously been validated to show a difference in tumorigenic potential between CSCs and non-CSCs based on CD133 expression (Bao et al., 2006; Eyler et al., 2011; Guryanova et al., 2011; Lathia et al., 2010; Li et al., 2009) . Cells with CSC properties were also enriched by their high expression levels of integrin 6 using a flow cytometry approach as previously described (Lathia et al., 2010) . In vitro, CSCs were maintained as tumorsphere cultures in NeuroBasal medium supplemented with sodium pyruvate, glutamine, B27 supplement, EGF, basic FGF, penicillin and streptomycin (Life Technologies), and non-CSCs were maintained as adherent cultures in D-MEM containing 10% fetal bovine serum. CSCs were differentiated by the removal of EGF and bFGF and the addition of 10% fetal bovine serum.
Proliferation, sphere formation, and tumorigenicity assays
To assess cell proliferation and survival over time, 1000 cells were plated in 96-well plate format, and total ATP content per well was measured using a CellTiter-Glo assay (Promega).
The resulting chemiluminescence was quantified with a Perkin Elmer luminometer and is displayed as total luminescence.
To estimate stem cell frequency in the cell population, tumor sphere formation assays were performed with limiting cell dilutions in 96-well plates in NeuroBasal media supplemented with sodium pyruvate, glutamine, B27 supplement, EGF, basic FGF, penicillin and streptomycin. To assess tumorigenicity of the cells, we used immunocompromised nude mice (nu/nu) to perform subcutaneous or intracranial (orthotopic for glioma) xenograft tumor formation assays.
Intracranial tumor implantation was performed as previously described (Lathia et al., 2010) .
CSCs (1,000 or 10,000) pretreated with non-targeting or Cx46 shRNA constructs were implanted into the right hemisphere of 4-6 week old mice in 20 µl of media devoid of growth factors. Mice were monitored daily for the development of neurological signs, at which point they were sacrificed. Subcutaneous tumors were measured with a caliper three times per week, and the volumes of the tumors were estimated using the formula ½ x L x W x H (Tomayko and Reynolds, 1989) . In both xenograft models where the cells L0 were used (Deleyrolle et al., 2011b; Siebzehnrubl et al., 2013) , intraperitoneal injection was used to deliver chemicals;
Temozolomide (5 mg/kg B.W., 3x/week), 1-Octanol (350 mg/kg B.W., 3x/week), Carbenoxolone (50 mg/kg B.W., 3x/week), and 4-Methyl-4-Heptanol (50 mg/kg B.W., 3x/week). The rate of symmetric stem cell division was estimated based on growth measurements using a previously published algorithm (Deleyrolle et al., 2011a) .
To understand the mechanism by which Cx46-depleted CSCs still formed tumors, although with longer tumor latency, DNA and RNA were extracted from shRNA-transduced GBM CSCs prior to xenografting, as well as from xenografts formed at 28-31 days following intracranial injection of transduced cells. The transduced cells were lysed with QIAzol (Qiagen), and xenograft tumor tissue was stabilized with Allprotect Tissue Reagent (Qiagen) and kept frozen at -80°C until purification of RNA and DNA according to the manufacturer's instructions. To quantify lenti provirus copy number, which is proportional to transduced gene expression, extracted DNA was analyzed by Lenti-X™ Provirus Quantitation Kit (Clonetech) and normalized to the prostaglandin E2 receptor 2 copy number determined by Sybr Green real-time qPCR using human-specific primers for PTEGR2 (Ren et al., 2013) . To determine the relative abundance of Cx46 and Sox2 transcript levels among the samples, cDNA was constructed from extracted RNA using Q-script (Qiagen) and subjected to SYBRGreen qPCR using primers against Cx46 and Sox2. For normalization, we also quantified GAPDH transcript levels by qPCR using human-specific primers. Using this approach, we detected the viral insert in tumors that formed from Cx46 knockdown cells (data not shown).
Immunofluorescence analysis
Cryosections were blocked with a PBS solution containing 10% normal goat serum (Sigma) and 0.1% Triton X-100 (Sigma). Sections were incubated overnight at 4°C using antibodies against Sox2 (R&D Systems, 1:40 -1:200), Cleaved caspase 3 (Cell Signaling, 1:500), and Ki67 (Leica Biosystems, 1:500). Following primary antibody incubation, sections were washed three times prior to incubation with appropriate secondary antibodies for 2 hr at room temperature. Prior to coverslip application, nuclei were counterstained with Hoechst, and imaging was performed using a Leica SP-5 confocal microscope as previously described (Lathia et al., 2010) . Images were processed and assembled in Photoshop (Adobe).
Quantitative PCR and immunoblot analysis
To determine the expression levels of connexins, Sox2, or the copy number of PTGER2, the For immunoblot analysis, cells grown as tumor spheres were harvested by centrifugation, and adherent cells were collected by scraping off the plate followed by centrifugation. The cell pellets were snap frozen by dropping the tubes into a pool of liquid nitrogen. Cells were lysed in 10 mM Tris HCl, pH 7.4; 0.5% IGEPAL CA-630 (weight/volume); 150 mM NaCl; 1 mM EDTA; 2 mM sodium orthovanadate; 1 mM PMSF; and a 1:100 dilution of protease inhibitor cocktail for mammalian cells (P8340 Sigma). Total protein concentration of the lysate was estimated accordingly using Protein Assay Dye (Bio-Rad) with a BSA standard (Thermo) as reference.
After denaturation according to Laemmli, 10-20 µg of total protein per sample was separated by SDS polyacrylamide gel electrophoresis (T=7.5% C=2.1%). Separated proteins were electrotransferred to a PVDF membrane, and the molecule of interest was detected by immunoblotting using specific antibodies against Cx46 (US Biological), Cx43 (Cell Signaling), Sox2 (R&D Systems), Olig2 (Millipore), Tubulin (Sigma), and Actin (Santa Cruz). Blots were visualized by incubating with horseradish peroxidase-conjugated secondary antibody and ECLplus (Thermo Scientific, Rockford, IL) substrate followed by capturing of the chemiluminescence signal with X-ray film.
Validation of Cx46 antibody
To obtain genuine human Cx46 protein that could be utilized to identify a specific anti-human Cx46 antibody, we generated a Cx46 expression plasmid by subcloning human Cx46 cDNA (Cat# RDC0535, R&D Systems, Minneapolis, MN) restriction enzyme fragment (HindIII/XbaI) into the corresponding sites of the pEGFP-N3 plasmid. Cells expressing Cx46 at low levels (NIH3T3 fibroblasts and T4121 non-CSCs) were transfected with the resulting expression plasmid using calcium phosphate co-precipitation. Two days after transfection, cells were lysed, and lysates were analyzed by immunoblotting and compared with lysates from parental cells
and T4121 CSCs. We tested multiple commercially available anti-human Cx46 antibodies and found that a rabbit polyclonal anti-Cx46 antibody (c7858-07D, U.S. Biological) was able to detect a band with increased intensity (between the 50-and 64-kDa molecular weight markers)
in lysates from Cx46 cDNA expression plasmid-transfected cells, indicating that this antibody recognizes human Cx46 connexin protein.
